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ABSTRACT These studies were undertaken to extend
emerging evidence that 2 adrenergic receptor (2AR)
agonists, in addition to their bronchorelaxing effects, may
have broad anti-inflammatory effects in the lung following
onset of experimental acute lung injury (ALI). Young
male C57BL/6 mice (25 g) developed ALI following
airway deposition of bacterial LPS or IgG immune com-
plexes in the absence or presence of appropriate stereo-
isomers (enantiomers) of 2AR agonists, albuterol or
formoterol. Endpoints included albumin leak into lung
and buildup of polymorphonuclear neutrophils and cyto-
kines/chemokines in bronchoalveolar fluids. Both 2AR
agonists suppressed lung inflammatory parameters
(IC5010
7 M). Similar effects of 2AR agonists on
mediator release were found when mouse macrophages
were stimulated in vitro with LPS. The protective effects
were associated with reduced activation (phosphoryla-
tion) of JNK but not of other signaling proteins. Collec-
tively, these data suggest that 2AR agonists have broad
anti-inflammatory effects in the setting of ALI. While
2AR agonists suppress JNK activation, the extent to which
this can explain the blunted lung inflammatory responses in
the ALI models remains to be determined.—Bosmann, M.,
Grailer, J. J., Zhu, K., Matthay, M A., Vidya Sarma, J.,
Zetoune, F. S., Ward, P. A. Anti-inflammatory effects of 2
adrenergic receptor agonists in experimental acute lung
injury. FASEB J. 26, 2137–2144 (2012). www.fasebj.org
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Acute lung injury (ALI) and acute respiratory dis-
tress syndrome (ARDS) are conditions of acute inflam-
matory injury in human lungs, associated with polymor-
phonuclear neutrophil (PMN) accumulation in alveolar
spaces and in adjacent capillaries, together with fibrin
deposits and edema fluid in the same areas. The presence
of C5a and neutrophils in bronchoalveolar lavage fluids
(BALFs) indicates that complement activation occurs
during ALI and ARDS (1). These inflammatory responses
are, as expected, associated with defective gas exchange
between alveolar spaces and blood in the interstitial
capillaries of the lung. The frequency of ALI in the
United States is 200,000 cases/yr, with a mortality that
approaches 40% (2). In some cases of ALI and ARDS,
permanent fibrosis or bronchopulmonary dysplasia (in
infants) develops, resulting in disabling lung function.
Since the causes of ALI and ARDS are poorly under-
stood, treatment is currently limited to supportive
therapy.
The initial line of evidence to suggest that the use of
2 adrenergic receptor (2AR) agonists produce bene-
ficial effects during ALI and ARDS was related to their
ability to enhance clearance of alveolar edema fluid (3,
4). There is emerging evidence that transmitters of the
cholinergic autonomic nervous system function in an
anti-inflammatory manner, suppressing release of pro-
inflammatory mediators from macrophages (5). Re-
cently, we reported that the adrenergic system, via inter-
action of 2 adrenergic receptors with catecholamines
(epinephrine, norepinephrine), brings about a proin-
flammatory outcome associated with intensified lung in-
flammatory injury (6). It was also shown that cat-
echolamines are produced by phagocytes (neutrophils
and macrophages). 2AR agonists (such as albuterol)
have long been used to induce upper airway bronchore-
laxation via induction of cAMP in bronchial smooth
muscle cells in humans with obstructive pulmonary dis-
eases, such as asthma (7). There are suggestions that
2AR agonists have additional actions in varying circum-
stances, such as enhancing clearance of pulmonary
edema fluid in individuals with high-altitude sickness (8)
and in animals after acid aspiration (9). The agonists also
attenuate the effects of lung ischemia (10) and inhibit
pulmonary inflammation after inhalation of bacterial
lipopolysaccharide (LPS) in humans (11). A common
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explanation for the diverse effects of 2AR agonists is
elusive. In the current studies, we found that 2AR
agonists have potent anti-inflammatory effects in experi-
mental models of ALI, the outcomes being related to
reduced levels in lung of proinflammatory mediators
(chemokines, cytokines) and diminished accumulation of
neutrophils in lung. While the presence of 2AR agonists
suppressed Jun-N-terminal kinase (JNK) activation by
30–40% and not other signaling molecules, it remains
to be proven whether this is the predominant reason for
the anti-inflammatory effects of the 2AR agonists.
Broadly, these findings may have therapeutic applications
for ALI/ARDS and other lung inflammatory conditions




Male C57BL/6J and IL-10/ mice (6–10 wk, 25 g) were
purchased from Jackson Laboratories (Bar Harbor, ME, USA)
and housed under specific pathogen-free conditions. All
procedures were performed in accordance with the U.S.
National Institutes of Health guidelines and the University
Committee on Use and Care of Animals, University of Mich-
igan.
Models of ALI
For LPS-induced ALI (LPS-ALI), mice were anesthetized (12,
13), the trachea was surgically exposed, and 40 l phosphate-
buffered saline (PBS) containing 50 g LPS (Escherichia coli,
O111:B4; Sigma-Aldrich, St. Louis, MO, USA) was slowly
injected intratracheally during inspiration. Sham-treated
mice received 40 l PBS intratracheally. IgG immune com-
plex (IgGIC)-induced ALI (IgGIC-ALI) mice received 125 g
rabbit anti-bovine serum albumin (BSA) IgG (MP Biomedi-
cals, Solon, OH, USA) intratracheally, followed by intrave-
nous injection of 0.5 mg BSA (Sigma-Aldrich, St. Louis, MO,
USA). At the end of experiments, the lungs were flushed with
1 ml PBS to obtain BALFs. After centrifugation, BALF cells
were counted in a hemocytometer, and cell-free BALF was
stored at 80°C.
Histopathology
Lungs were fixed in 10% formalin overnight, and 3-m
paraffin-embedded sections were stained with hematoxylin
and eosin. Digital images (40/0.9, 100/1.4) were ac-
quired using an Olympus BH2 microscope (Olympus, Center
Valley, PA, USA).
Isolation and incubation of macrophages
Thioglycollate-elicited murine macrophages were obtained
and cultured, and supernatant fluids were harvested, as
described elsewhere (12). For isolation of alveolar macro-
phages, the lungs were lavaged multiple times with PBS (0.5
mM EDTA). The mouse lung alveolar epithelial cell line 12
(MLE-12) and SV40-transformed mouse macrophage line
(MH-S) cells were gifts from Dr. J. Weinberg (University of
Michigan).
Measurement of BALF albumin and mediator
concentrations
Mouse albumin in BALF was detected by ELISA (Bethyl
Laboratories, Montgomery, TX, USA). Mouse cytokines and
chemokines were detected with a bead-based multiplex assay
(Bio-Plex Pro; Bio-Rad, Hercules, CA, USA), as described
earlier (13). In addition, mouse IL-6, IL-10, and TNF- were
measured by ELISA kits (R&D Systems, Minneapolis, MN,
USA).
Analysis of signaling pathways
Macrophages were lysed (Bio-Plex Cell Lysis Kit; Bio-Rad),
and the following signaling pathways were analyzed with
phosphorylation-specific antibodies in a bead-based assay
format (Bio-Plex Phospho 9-Plex; Bio-Rad): Akt (Ser473),
c-Jun (Ser63), CREB (Ser133), ERK1/2 (Thr202/Tyr204,
Thr185/Tyr187), JNK (Thr183/Tyr185), MEK1 (Ser217/
Ser221), NF-B (Ser536), p38 MAPK (Thr180/Tyr182), and
STAT3 (Ser727).
Reagents
The following reagents were used: LPS (E. coli, 0111:B4,
Sigma-Aldrich); R-albuterol, S-albuterol, R,R-formoterol and
S,S-formoterol (kindly provided by Sepracor Corp., Marlbor-
ough, MA, USA); SP600125 (JNK inhibitor with IC5040 nM
for JNK-1 and JNK-2, IC5090 nM for JNK-3; InvivoGen, San
Diego, CA, USA); 2	,5	-dideoxyadenosine and SQ22536 (ad-
enylate cyclase inhibitors; Santa Cruz Biotechnology, Santa
Cruz, CA, USA); neutralizing monoclonal rat anti-mouse
IL-10 IgG1 and rat IgG2 isotype control antibodies (R&D
Systems).
Statistical analysis
All values are expressed as means 
 se. Data sets were
analyzed by 1-way ANOVA or Student’s t test (GraphPad
Prism 5.03; GraphPad Software, La Jolla, CA, USA), and
differences were considered significant at values of P  0.05.
In vitro experiments were performed independently 3 times,
and n  5 mice/group were used for in vivo experiments.
RESULTS
Effects of 2AR agonists on ALI following deposition
of IgGIC or LPS
To obtain data related to the anti-inflammatory activities
of 2AR agonists, the experiments described in Fig. 1
were carried out. In Fig. 1A, ALI was induced by
intrapulmonary deposition of IgGICs, and injury was
quantified by levels of mouse albumin in BALFs. Details
of these models are described elsewhere (14, 15). It is
clear that only certain stereoisomers (enantiomers) of
albuterol and formoterol suppressed the albumin leak,
namely, S-albuterol and R,R-formoterol (Fig. 1A, bars 4
and 5). The compounds by themselves had no effect on
albumin content in BALFs (data not shown). When the
ALI model using LPS was employed, remarkably similar
patterns of suppression of LPS-induced ALI (reduced
albumin leak into the alveolar compartment) were
found, with S-albuterol and R,R-formoterol being
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highly suppressive (Fig. 1B). The severity of lung dam-
age (albumin leakage, PMN counts) was more intensive
in IgGIC-ALI as compared to LPS-ALI, which is consis-
tent with our earlier reports on these two ALI models.
Figure 1C shows that the lung instillation of 106M
S-albuterol or R,R-formoterol greatly suppressed
buildup of PMNs (nearly 70%) in BALFs during IgGIC-
induced ALI and in LPS-induced ALI. It is well docu-
mented that the IgGIC and LPS models of ALI require
participation of PMNs (16). Figure 1D demonstrates
dose-response curves for 2AR agonist inhibition of ALI
induced by IgGICs, as measured by albumin buildup in
BALFs. The IC50 values for S-albuterol and R,R-formot-
erol effects in lung were 107M. Finally, using the
IgGIC model of ALI, the data in Fig. 1E demonstrate
the effects of the presence in BALFs of either of the two
2AR agonists (10
6M) on the buildup of proinflam-
matory cytokines and chemokines in BALFs, several of
which are required for recruitment of PMNs and full
development of ALI (reviewed in ref. 16). The data are
expressed as percentage reduction in mediator levels,
and the positive control values (pg/ml) are indicated
for each mediator. Minimal effects were seen on levels
of IL-6 and IL-12 (Fig. 1E, bars 1 and 2). The most
consistent reductions caused by 2AR agonists (espe-
cially R,R-formoterol) involved KC (CXCL1), MCP-1
(CCL2), and TNF-, all of which have been shown to
play a facilitative role in this type of ALI (16). Accord-
ingly, it seems that the suppressive effects on 2AR
agonists in this ALI model appear to be linked to a
reduction in cytokine and chemokine levels. Such
mediators are known to be required for PMN recruit-
ment and PMN activation, as well as activation of lung
macrophages.
Effects of 2AR agonists on in vitro production of
macrophage mediators and signaling molecules
In Fig. 2, we switched to in vitro use of LPS-stimulated
mouse peritoneal exudate (thioglycollate)-induced
macrophages (PEMs) in the presence or absence of
2AR agonists or selective JNK inhibitor SP600125. In
Fig. 2A, the presence of 106 M S-albuterol or R,R-
formoterol consistently caused reduced levels of IL-6
(bar 1), KC (CXCL1; bar 3), and TNF- (bar 6) in
supernatant fluids of LPS-treated macrophages. KC and
TNF- have been shown to be important mediators for
recruitment of PMNs and activation of lung macro-
phages in the ALI model employed (17, 18). In Fig. 2B,
PEMs were incubated with LPS, and activation (phos-
phorylation) of JNK was determined as a function of
Figure 1. Effects of 2AR agonists during ALI. A) Acute lung injury in young adult (25 g) C57BL/6 male mice 6 h after
intratracheal (i.t.) administration of 125 g anti-BSA IgG and intravenous (i.v.) infusion of 1 mg BSA, resulting in
IgGIC-induced ALI. Sham-treated mice received i.t. anti-BSA but no i.v. BSA. Isomeric forms (enantiomers) of 2AR agonists
were intermixed with the anti-BSA, all at 106 M. For each bar, n  12 mice. Endpoints were BALF mouse albumin as measured
by ELISA. B) ALI induced by i.t. administration of 50 g LPS 6 h earlier, resulting in ALI. Various enantiomers of albuterol were
used (as indicated), at 106 M, similar to the protocol in panel A. For each bar, n  10 mice. Endpoints were mouse albumin
in BALFs. C) Effects of 106 M S-albuterol or R,R-formoterol on BALF content of PMNs 6 h after onset of IgGIC-induced or
LPS-induced ALI. Virtually no PMNs were found in sham-treated BALFs. For each bar, n  10. D) Dose responses of S-albuterol
or R,R-formoterol (i.t.) on BALF albumin 6 h after onset of IgGIC-ALI. For each dose, n  5 mice. BALF albumin levels were
compared as a percentage of albumin in positive controls. E) BALF mediators in IgGIC-ALI mice 6 h after onset of reactions,
expressed as a percentage of positive controls (pg/ml; shown at right). S-albuterol or R,R-formoterol were present at 106 M.
Positive control reference values (pg/ml) are indicated for each of the 7 mediators. For each bar, n  6 mice. *P  0.05.
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time, using the bead-based assay system. Preliminary
studies showed that phosphorylation of signaling pro-
teins occurred during the first 60 min after addition of
LPS to PEMs (data not shown). It was clear that by 20
min, phospho-JNK was elevated, with a doubling of
activation by 60 min (Fig. 2B). When PEMs were
incubated with LPS (1 g/ml) for 1 h at 37°C, there
was 2.5-fold increase in phosphorylation of JNK (Fig.
2C), whereas in the copresence of 106 M S-albuterol
or R,R-formoterol, there were reductions (shown as
means) based on 4 separate experiments in phospho-
JNK of 31 and 35%, respectively. In companion
experiments, LPS-stimulated macrophages were incu-
bated in the absence or presence of 105, 106, or
107M S-albuterol or R,R-formoterol, and changes in
phospho-JNK were assessed. The phospho-amino acids
of the following signaling molecules were also evalu-
ated after LPS activation in the absence or presence of
106MS-albuterol or R,R-formoterol: Akt (Ser473), CREB
(Ser133), ERK1/2 (Thr202/Tyr204, Thr185/Tyr187),
JNK (Thr183/Tyr185), MEK1 (Ser217/Ser221), NF-B
(Ser536), p38 MAPK (Thr180/Tyr182), STAT3 (Ser727).
Surprisingly, the only signaling molecule consistently af-
fected by 2AR agonists was phospho-JNK.
We also employed SP600125, a selective, reversible
ATP-competitive inhibitor of JNK (19). PEMs were
activated by LPS in the absence or presence of
SP600125 (1.0–100 M), and effects on TNF- release
were determined and expressed as percentage reduc-
tion (Fig. 2D). As is apparent, this JNK inhibitor had an
IC50 of 10 M. Collectively, these data suggest that
the inhibitory effects of 2AR agonists on LPS-mediated
release of TNF- and other mediators from PEMs may
be linked to the ability of these agonists to suppress JNK
activation.
Additional studies were done to further define the
suppressive effects of 2AR agonists on TNF- release
from LPS-activated PEMs. In Fig. 3A, R,R-formoterol
was used in a range of 0.01–100 nM. The IC50 for this
2AR agonist in terms of reduced release of TNF- was
0.07 nM, while the IC50 for S-albuterol was much higher
(12 M; Fig. 3B). When supernatant fluids from LPS-
stimulated macrophages (shown in Fig. 3A, B) were
assayed for other mediators relevant to IgGIC- and
LPS-induced ALI, we found that for release of MCP-1,
MIP-1, KC, and IL-6, the IC50 values for R,R-formot-
erol were 0.6, 0.85, 1.0, and 0.8 nM, respectively (data
not shown). For S-albuterol, the in vitro IC50 values were
2, 1, 10, and 10 M, respectively. Accordingly,
R,R-formoterol had broad inhibitory effects on media-
tor release from macrophages, while S-albuterol was
much less effective. Why the 2AR agonists were equally
inhibitory in vivo (Fig. 1D) but showed different efficacy
in vitro (Figs. 2 and 3) is not known. In Fig. 3C, the
selective 2AR antagonist ICI-118,551 was used at 0.1 or
1.0 M in the copresence of 106 M R,R-formoterol. It
was clear that the presence of this compound largely
blocked the ability of R,R-formoterol to suppress TNF-
release from LPS-stimulated PEMs, which is consistent
with R,R-formoterol working via 2AR. Because the
2AR agonists used in these studies have been well
documented to cause bronchial smooth muscle relax-
ation via induction of cAMP (20), studies were carried
out to determine whether production of cAMP in
LPS-stimulated PEMs might be linked to the suppres-
sive effects of 2AR agonists on TNF- release from
PEMs. The experiments described in Fig. 3D, E were
performed. PEMs were stimulated with LPS in the
absence or presence of 1 M R,R-formoterol, and
TNF- release after 4 h was evaluated. The copresence
of the adenylate cyclase inhibitors 2	,5	-dideoxyadenos-
ine (2–200 M; Fig. 3D) or SQ22536 (1–100 M; Fig.
3E) failed to reverse the inhibitory effects of R,R-
formoterol on TNF- release from PEMs. TNF- release
was suppressed by nearly 80% in the presence of the
2AR agonist, and no reversal in this suppression was
found in the presence of 2 M 2	,5	-dideoxyadenosine.
Similarly, SQ22536 did not reverse the suppressive
effects of R,R-formoterol on TNF-. At higher doses, in
the absence of R,R-formoterol, both inhibitors caused
nonspecific reductions in LPS-induced release of
TNF-. The data suggest that the suppressive effects of
Figure 2. Effects of 2AR agonists and JNK inhibitors on mediator production in vitro. A) Effects of 2AR agonists on mediator
production in LPS-stimulated (1 g/ml) mouse PEMs (2106) for 4 h at 37°C, expressed as percentage reduction. Positive
control reference values (pg/ml) are indicated for each of the 7 mediators. As indicated, 106 M S-albuterol or R,R-formoterol
was present at the time of addition of LPS to PEMs. Percentage reduction is relative to LPS-stimulated PEM in the absence of
2AR agonists. Reference values (pg/ml) for positive controls are shown in box. For each bar, n  6 samples. B) Activation
(phosphorylation) of JNK in LPS-stimulated PEMs as a function of time, using control (ctrl) PEMs (non-LPS exposed) as the
reference point. Phospho-JNK was measured in cell lysates as a function of time (min) after addition of LPS, using a bead-based
assay. For each bar, n  4 samples. C) Levels of phospho-JNK in LPS-stimulated PEMs in the absence or presence of 106 M
S-albuterol or R,R-formoterol 60 min after addition of LPS 
 2AR agonists. Results are from 4 separate experiments, in which
average reductions of JNK phosphorylation in the presence of S-albuterol or R,R-formoterol were 31 and 35%, respectively. For
each bar, n  4 samples. D) Dose response for SP600125 (JNK1/2 inhibitor) on release of TNF- from LPS-stimulated PEMs.
For each bar, n  4 samples. *P  0.05.
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R,R-formoterol are probably not linked to cAMP induc-
tion.
Next, we used MLE-12 cells. MLE-12 cells produced
abundant MCP-1 (CCL2) and KC (CXCL1) when stim-
ulated with LPS, but the presence of 106 M R,R-
formoterol or S-albuterol did not result in impaired
mediator release (data not shown). This is despite the
fact that alveolar epithelial cells are known to contain
abundant expression levels of 2AR, which are required
for clearance of intra-alveolar edema fluid (21).
Clearly, mediator release from LPS-stimulated MLE-12
cells was not reduced in the presence of 106 M
R,R-formoterol or S-albuterol.
Relevance of the induction of IL-10 to the
suppressive effects of 2AR agonists
We wanted to assess whether the suppressive effects of
2AR agonists on macrophages were mediated through
IL-10 production, which is known to inhibit cytokine
production by activated macrophages (22). When
PEMs (1106) were stimulated in vitro with LPS (1
g/ml) in the absence or presence of R,R-formoterol
(0.01–1,000 nM), PEMs produced IL-10 in the copres-
ence of LPS and R,R-formoterol, while production of
IL-10 with PEMs exposed to LPS in the absence of
R,R-formoterol was very low (100 pg/ml; Fig. 4A).
When freshly harvested mouse alveolar macrophages
were stimulated with LPS (1 g/ml), the cells pro-
duced IL-10 in the copresence of 1 M R,R-formoterol
or S-albuterol, with 6.5-fold and 2.0-fold increases in
IL-10, respectively, compared to treatment with LPS
alone (Fig. 4B). MH-S cells were also found to produce
IL-10 after LPS addition in the copresence of R,R-
formoterol or S-albuterol (Fig. 4C). As expected, R,R-
formoterol and S-albuterol reduced TNF- production
by 56 and 10%, respectively (Fig. 4C, solid bars; TNF-
concentrations shown on left y axis). When IL-10 was
measured in the same supernatant fluids, R,R-formot-
erol and S-albuterol enhanced IL-10 production by
3.0-fold and 1.5-fold, respectively (Fig. 4C, open bars;
IL-10 concentrations shown on right y axis). These data
are similar to the patterns found with alveolar macro-
phages and PEMs (Figs. 4B and 3A, B). Companion
studies were done to determine whether the presence
of neutralizing antibody to mouse IL-10 would reverse
the suppressed levels of TNF- released by LPS-stimu-
lated MH-S cells in the presence of R,R-formoterol or
S-albuterol. As shown in Fig. 4D, there was no convinc-
ing evidence that IL-10 neutralization was able to
reverse the inhibitory effect of the 2AR agonists at the
time points studied. Finally, when PEMs were obtained
from wild-type and IL-10/ mice and stimulated with
LPS, the presence of 106 M R,R-formoterol still re-
duced TNF- production in wild-type cells by nearly
80% (data not shown). That R,R-formoterol was able to
suppress TNF- production in IL-10/ PEMs suggests
that its ability to reduce TNF- production is not
associated with release of IL-10.
Histopathology of lungs
Figure 5 contains the histopathological features in ALI
lungs at 6 h after deposition of IgGICs, using hematox-
Figure 3. In vitro dose responses of
LPS-stimulated PEMs in the absence
or presence of 2AR agonists, using
release of TNF- as the endpoint.
A) TNF- release in the presence of
increasing concentrations of R,R-for-
moterol (0.01–100 nM). B) Similar
experiments using S-albuterol (0.1–10
M). Text describes parallel effects
on MCP-1, MIP-1, KC, and IL-6.
C) Similar experiments with R,R-for-
moterol (1 M) in the absence or
presence of ICI-118,551 (selective 2AR antagonist). D) Release of TNF- from PEMs activated with LPS (1 g/ml) for 4 h
at 37°C in the absence or presence of 1 M R,R-formoterol and, as indicated, in the copresence of 1–200 M
2	,5	dideoxyadenosine (inhibitor of adenylate cyclase). E) Experiments similar to those in D, using another adenylate
cyclase inhibitor (SQ2536) at concentrations of 1–100 M. For all bars, n  5 samples. *P  0.05, **P  0.01, ***P  0.001.
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ylin-and-eosin stains on paraffin-embedded sections. In
Fig. 5A, the section from normal lung showed alveoli
devoid of edema fluid, fibrin deposits, red blood cells
(RBCs), and PMNs. In striking contrast, in the positive
controls (Fig. 4B), the alveolar spaces showed extensive
hemorrhage, fibrin deposits, and PMN accumulations
together with edema. The protective features of 2AR
agonists are shown in Fig. 5C (S-albuterol) and Fig. 5D
(R,R-formoterol), where there were PMNs in the inter-
stitial capillaries but very few in alveolar spaces, which
were also largely devoid of fibrin deposits and RBCs.
DISCUSSION
There are suggestions in the literature that 2AR
agonists may have anti-inflammatory effects in lung. For
instance, histamine-induced extravasation of plasma
protein in guinea-pig skin was reduced in the presence
of either albuterol or formoterol (23). When guinea-
pig lungs were exposed in vitro to histamine or brady-
kinin, the vascular leak was attenuated in the copres-
ence of either 2AR agonist (23). In humans with
pulmonary edema associated with high-altitude acute
sickness or with ARDS, 2AR agonists caused enhanced
clearance of alveolar edema (1, 24–26). Formoterol in
conjunction with a steroid reduced up-regulation of
ICAM-1 and VCAM-1 in IL-1-treated fibroblasts (27).
Formoterol also suppressed release of mast cell media-
tors (such as histamine and leukotrienes) from human
lung (28). During ARDS, 2AR agonists may have the
following effects on lung inflammatory responses in
lung: reduced endothelial permeability and enhanced
clearance of alveolar fluid, increased surfactant produc-
tion, reduced cytokine production, reduced adhesion
molecule expression on endothelial cells, and increased
mucociliary clearance, all of which would be expected to
attenuate the lung inflammatory response (29).
AR agonists (1AR, 2AR) may reduce PMN seques-
tration in the lung following airway delivery of LPS.
Pretreatment of mice with the 1AR agonist dobut-
amine reduced PMN content in BALFs by 30%, to-
gether with reduced levels of IL-6, IL-10, and MIP-2
(CXCL2) (30). There is convincing evidence that 2AR
agonists cause reductions in ICAM-1 and VCAM-1 in
human bronchial epithelial cells, resulting in reduced
adhesiveness of PMNs to these cells (31–33). Increased
levels of cAMP in PMNs exposed to 2AR agonists also
resulted in reduced adherence of PMNs to bronchial
epithelial cells (32). Human lung fibroblasts exposed to
2AR agonists impaired the ability of IL-1 to up-
regulate ICAM-1 and VCAM-1 (27). It appears that
exposure of endothelial cells to 2AR agonists resulted
in reduced paracellular movement across monolayers
of endothelial cells of FITC-dextran, together with
induction of NO formation (34, 35). Collectively, 2AR
agonists seem to have a variety of anti-inflammatory
outcomes due to effects on PMNs, lung fibroblasts,
bronchial epithelial cells, and endothelial cells. How-
ever, the extent to which these responses can be linked
to induction of cAMP is not clear. Another response to
Figure 4. Suppression of TNF- production by 2AR agonists is independent of IL-10. A, B) Production of IL-10 by
LPS-stimulated mouse PEMs (A) and mouse alveolar macrophages (M; B). Cells were stimulated by LPS (1 g/ml) for 4 h in
the absence or presence of R,R-formoterol or S-albuterol (both at 106 M). C) Production of TNF- (solid bars, left y axis) and
IL-10 (open bars, right y axis) in LPS-stimulated MH-S cells (immortalized mouse lung macrophages) in the presence or absence
of 1  106 M R,R-formoterol or S-albuterol, 4 h. D) Similarly treated cells were also exposed to LPS in the presence or absence
of 2 different concentrations of neutralizing antibody to IL-10 at the indicated concentrations. For all bars, n  5 samples. *P 
0.05.
Figure 5. Histopathology of mouse lungs in normal lungs and
lungs after ALI following airway deposition of IgGICs. A)
Histological features of normal mouse lung. B) Positive
control (acutely injured lung induced by airway deposition of
IgGICs) 6 h after induction of ALI. C, D) Lungs after
initiation of ALI in the copresence of 106 M S-albuterol (C)
or R,R-formoterol (D). All panels are from paraffin-embed-
ded sections stained with hematoxylin and eosin (40 view).
Insets: 100 view.
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2AR agonists that could have anti-inflammatory out-
comes is induction of IL-10, which is described in this
report, as well as elsewhere (36).
There is little question that 2AR agonists activate
adenylate cyclase in bronchial smooth muscle cells,
causing generation of cAMP, resulting in smooth mus-
cle relaxation. This is the basis for the use of 2AR
agonists in the settings of chronic obstructive pulmo-
nary disease and in asthma. The extent to which such
treatment may reduce the amount of inflammatory
cells in the upper airways is unclear. As noted, 2AR
agonists suppressed distal airway ALI (edema, fibrin
deposition, PMN accumulation, and alveolar hemor-
rhage; Fig. 5). The mechanisms of such effects appear
to be unrelated to effects on cAMP levels (Fig. 3) and
may be linked to suppressed production of mediators
via inhibition of the JNK signaling pathway of CXC
chemokines that activate PMNs (e.g., KC; Fig. 1). In
addition, TNF- levels in BALFs were sharply reduced
in the presence of 2AR agonists, as was release of
TNF- and other proinflammatory mediators from
LPS-stimulated macrophages (see discussion of Fig. 3 in
Results). These studies suggest that 2AR agonists func-
tion via a variety of mechanisms to suppress acute
inflammatory responses in lung.
One might note that in Fig. 1E, there are some
striking differences in inhibitory effects of 2AR ago-
nists on BALF mediators when data with R,R-formot-
erol are compared to results with S-albuterol. It may be
that the two 2AR agonists have different effects on
some of the mediator responses because of differences
in the way in which formoterol and albuterol bind to
2AR and differences in their modes of action and
potency. Formoterol has fast and long-lasting effects
and is more potent than albuterol (a short-acting
agonist) at the same dosage concentration (37). Fur-
ther, even when two long-acting 2AR agonists, such as
formoterol and salmeterol, were used, their levels of
inhibition of TNF- and GM-CSF release from LPS-
treated monocyte derived macrophages were quite
different (38). In addition, differences in efficacy were
as much as 50%, with formoterol being more effective
than salmeterol in suppressing TNF- release. There-
fore, it is not surprising that, although formoterol and
albuterol are both 2 agonists, depending on the
endpoint (cytokine/chemokine release), these two
2AR agonists may display quite divergent results.
An important question is the intrapulmonary con-
centration of 2AR agonists. In a report by Atabai et al.
(39), ventilated patients with pulmonary edema (hydro-
static, n10; ALI, n12) received albuterol delivery via
aerosol for 6 h, at which time edema fluid was aspi-
rated, revealing the albuterol level of 106M, which was
the concentration of albuterol and formoterol used in
the current experimental study. The extent to which
2AR agonists being delivered into lungs of humans by
aerosol reduces the intensity of ALI is debatable (see
above). Also, the pharmacokinetics of 2AR agonists in
lung are poorly understood, raising the question about
the duration over which such levels of 2AR agonists
can be maintained in human lungs.
Several clinical studies have investigated the efficacy
of 2AR agonists in the treatment of ALI/ARDS. A
recent retrospective study of 86 mechanically ventilated
patients with ALI treated with albuterol (salbutamol) by
inhalation (2.2 mg/d) concluded that there was
improvement in survival and reduction in ALI when
compared to the use of low-dose albuterol (2.2
mg/d) (25). In another clinical trial involving 66
patients with ALI, albuterol was infused intravenously,
resulting in a significant reduction in lung water,
although these patients had a higher incidence of
supraventricular arrhythmias (40). In contrast, a re-
cently published fairly large clinical study (randomized
phase III trial) with aerosolized albuterol failed to
demonstrate clinical efficacy based on mortality, venti-
lator-free days, blood oxygenation, and plasma levels of
IL-6 and IL-8 (on d 1 and 3 during treatment; ref. 41).
It seems that it is too early to determine whether
discrepancies in the 3 reports are due to differences in
design of the studies, or explained by different clinical
endpoints, differences in routes of administration of
the drugs, or other factors. Clearly, our experimental
results indicate that 2AR agonists are effective in
confining the tissue-destructive inflammatory response
underlying ALI in the experimental setting when these
agonists are delivered via the airways during the devel-
opment of ALI. There is no current information about
the protective effects of 2AR agonists if administration
is delayed after the onset of ALI. In the clinical setting,
early initiation of treatment before the patient requires
positive-pressure ventilation (42) may be a critical de-
terminant that could influence the potential beneficial
effect of 2AR agonists on the course of clinical lung
injury, ALI/ARDS.
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